Tag: ADCT-402
ADC Therapeutics and Mitsubishi Tanabe Pharma Sign Exclusive License Agreement to...
ADC Therapeutics and Mitsubishi Tanabe Pharma Corporation have signed an exclusive license agreement for the development and commercialization of loncastuximab tesirine (ADCT-402; Zynlonta®; ADC...
European Commission Grants Orphan Drug Designation to Loncastuximab Tesirine
The European Commission has granted Orphan Drug Designation to loncastuximab tesirine (Zynlonta®; ADC Therapeutics); previously known as ADCT-402, a CD19-targeted ADC, for the treatment...
Results of LOTIS-2 Study of Loncastuximab Tesirine Shows Substantial Single-agent Activity,...
Results of LOTIS-2, a multicenter, open-label, single-arm Phase II clinical trial evaluating the safety and efficacy of single-agent loncastuximab tesirine-lpyl (Zynlonta™; ADC Therapeutics; previously...
Sterling Pharma Solutions Acquires ADC Biotechnology
Global contract development and manufacturing organization (CDMO), Sterling Pharma Solutions, has announced the acquisition of ADC Biotechnology, a UK-based bioconjugation development services business specializing...
U.S. FDA Accepts Biologics License Application and Grants Priority Review for...
The U.S. Food and Drug Administration (FDA) has accepted the Biologics License Application (BLA) for loncastuximab tesirine, previously known as ADCT-402.
The investigational agent is...
FDA Accepts Biologics License Application and Grants Priority Review for Loncastuximab...
The U.S. Food and Drug Administration (FDA) has accepted its Biologics License Application (BLA) from ADC Therapeutics for loncastuximab tesirine, previously know as ADCT-402,...
First Patients Dosed with Combination of Loncastuximab Tesirine + Ibrutinib in...
Diffuse large B-cell lymphoma (DLBCL) and mantle cell lymphoma (MCL) are two distinct subtypes of non-Hodgkin lymphoma (NHL). These hematological malignancies are associated with...
Loncastuximab Tesirine Shows Early Promise in Patients with Relapsed/Refractory B-cell Non-Hodgkin...
Loncastuximab tesirine, also known as ADCT-402, an investigational antibody-drug conjugate being developed by ADC Therapeutics, showed signs of clinical activity in patients with relapsed/refractory...
Freenome Enters Biomarker Development Collaboration with ADC Therapeutics
Swiss-based ADC Therapeutics, an oncology-drug development company specializes in the development of antibody drug conjugates (ADCs), and Freenome, a biotech company pioneering the a...
SOPHiA Genetics and ADC Therapeutics Partner for Biomarker Discovery in Pivotal...
ADC Therapeutics and SOPHiA GENETICS have entered into a collaboration to identify genomic markers associated with clinical response to loncastuximab tesirine (ADCT-402), an antibody...
